Evidence map›Paper›PMID 24740510›Full record

Trial reportJournal of immunology (Baltimore, Md. : 1950)2014

Functional avidity and IL-2/perforin production is linked to the emergence of mutations within HLA-B*5701-restricted epitopes and HIV-1 disease progression.

Marcus Buggert, Melissa M Norström, Marco Salemi, Frederick M Hecht, Annika C Karlsson

Open access · bronzeAbstract readClinical TrialComparative Study
In one paragraph

Trial report in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Perturbed CD8Scientific reports · 2017
    Article
  8. Article
  9. Article
  10. The influence of HLA/HIV genetics on the occurrence of elite controllers and a need for therapeutics geotargeting view.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Marcus BuggertDivision of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm S-141 86, Sweden;
Melissa M Norström
Marco Salemi
Frederick M Hecht
Annika C Karlsson
Karolinska Institutet · SEUniversity of California, San Francisco · USUniversity of Florida · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Transmission and Persistence of CTL and Drug Resistance MutationsP01AI071713 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HECHT, FREDERICK M · 2007 to 2011
$14.3M
Mentoring and Research in Integrative MedicineK24AT007827 · NCCIH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HECHT, FREDERICK M · 2013 to 2022
$1.8M
NCCIH NIH HHS K24 AT007827NIAID NIH HHS P01 AI071713NIAID NIH HHS P30 AI027763
6 · The paper itself

Abstract

Viral escape from HIV-1-specific CD8(+) T cells has been demonstrated in numerous studies previously. However, the qualitative features driving the emergence of mutations within epitopes are still unclear. In this study, we aimed to distinguish whether specific functional characteristics of HLA-B*5701-restricted CD8(+) T cells influence the emergence of mutations in high-risk progressors (HRPs) versus low-risk progressors (LRPs). Single-genome sequencing was performed to detect viral mutations (variants) within seven HLA-B*5701-restricted epitopes in Gag (n = 4) and Nef (n = 3) in six untreated HLA-B*5701 subjects followed from early infection up to 7 y. Several well-characterized effector markers (IFN-γ, IL-2, MIP-1β, TNF, CD107a, and perforin) were identified by flow cytometry following autologous (initial and emerging variant/s) epitope stimulations. This study demonstrates that specific functional attributes may facilitate the outgrowth of mutations within HLA-B*5701-restricted epitopes. A significantly lower fraction of IL-2-producing cells and a decrease in functional avidity and polyfunctional sensitivity were evident in emerging epitope variants compared with the initial autologous epitopes. Interestingly, the HRPs mainly drove these differences, whereas the LRPs maintained a directed and maintained functional response against emerging epitope variants. In addition, LRPs induced improved cell-cycle progression and perforin upregulation after autologous and emerging epitope variant stimulations in contrast to HRPs. The maintained quantitative and qualitative features of the CD8(+) T cell responses in LRPs toward emerging epitope variants provide insights into why HLA-B*5701 subjects have different risks of HIV-1 disease progression.

Indexed as

Base SequenceCell CycleCytokinesDisease ProgressionEpitopesGene Products, gagHIV-1HIV InfectionsHLA-B AntigensHumansInterleukin-2MaleMolecular Sequence DataMutationPerforinUp-RegulationCytokinesEpitopesGene Products, gagHLA-B*57:01 antigenHLA-B AntigensIL2 protein, humanInterleukin-2Perforin

Identifiers

PMID24740510
PMCPMC4046013
OpenAlexW1647345871

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.